Gurnet Point Capital
55 Cambridge Parkway Suite 401, Cambridge, MA, 02142, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Naveris | Sep 2022Led | $33 MSeries A | |
Alladapt Immunotherapeutics | Jun 2022Participated | $119 MOther Equity | |
Fairtility | May 2022Led | $15 MSeries A | |
Mahana Therapeutics | Aug 2021Led | $61 MSeries B | |
Zikani Therapeutics | Apr 2020Participated | $8 MSeries A | |
Alladapt Immunotherapeutics | Feb 2020Led | $60 MSeries C | |
Zikani Therapeutics | Apr 2018Led | $20 MOther Equity | |
BEFORE Brands | Mar 2017Led | $35 MSeries B | |
Crossover Health | Dec 2016Led | $92 MOther Equity | |
BEFORE Brands | Oct 2016Led | $13 MSeries A | |
Zikani Therapeutics | Mar 2015Led | $22 MSeries A | |
Naveris | Sep 2022Led | $33 MSeries A | |
Alladapt Immunotherapeutics | Jun 2022Participated | $119 MOther Equity | |
Fairtility | May 2022Led | $15 MSeries A | |
Mahana Therapeutics | Aug 2021Led | $61 MSeries B | |
Zikani Therapeutics | Apr 2020Participated | $8 MSeries A | |
Alladapt Immunotherapeutics | Feb 2020Led | $60 MSeries C | |
Zikani Therapeutics | Apr 2018Led | $20 MOther Equity | |
BEFORE Brands | Mar 2017Led | $35 MSeries B | |
Crossover Health | Dec 2016Led | $92 MOther Equity | |
BEFORE Brands | Oct 2016Led | $13 MSeries A | |
Zikani Therapeutics | Mar 2015Led | $22 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 4 | 1 |
| Series B | 2 | 0 |
| Series C+ | 1 | 0 |
| Other Equity | 2 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Mar '15 | 1 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 0 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 1 |
| Nov '16 | 0 |
| Dec '16 | 1 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 1 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 1 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 1 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 11 |
| Consumer & Lifestyle | 2 |
| Networks, Cloud & Communication | 1 |
| AI & Machine Learning | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 4 |
| $25M-$50M | 2 |
| $50M-$100M | 3 |
| $100M-$250M | 1 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 10 |
| Israel | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Advent Life Sciences | 2 |
| Novartis | 2 |
| Roche Ventures | 2 |
| SR One | 2 |
| AllerFund | 1 |
| BrightEdge | 1 |
| dRx Capital | 1 |
| Enavate Sciences | 1 |
| Equilibra Partners Management | 1 |
| JAZZ Venture Partners | 1 |
| KKCG | 1 |
| Lux Capital | 1 |
| Main Street Advisors | 1 |
| Nacre Capital | 1 |
| Red Tree Venture Capital | 1 |
| Roche Venture | 1 |
| TechU Ventures | 1 |
| WestRiver Group | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 9 | 82% |
| Participating | 2 | 18% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 6 | 67% |
| Co-led | 3 | 33% |
Team
Principal
Principal
Partner
Founder
Principal
Principal
Partner